3 Results for "

classical complement-mediated diseases

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "classical complement-mediated diseases" in MCE Product Catalog:

Crovalimab
Crovalimab
0 Images
Referencia número: HY-P99965
No. CAS: 1917321-26-6
Synonyms: SKY59; RO7112689; RG-6107

Target:  

Complement System

Áreas de investigación:  

Cardiovascular Disease Metabolic Disease

Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
Riliprubart
Riliprubart
0 Images
Referencia número: HY-P990091
No. CAS: 2756228-76-7
Synonyms: SAR 445088

Target:  

Complement System Fc Receptor (FcR)

Áreas de investigación:  

Neurological Disease Inflammation/Immunology

Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Cemdisiran
Cemdisiran
0 Images
Referencia número: HY-145720
No. CAS: 1639264-46-2
Synonyms: ALN-CC5
Target:  

Complement System Small Interfering RNA (siRNA)

Áreas de investigación:  

Metabolic Disease

Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
Assay Types